

12 October 2009

Proposal to change the format of Section H

PHARMAC is seeking feedback on a proposal to change the format of Section H for Hospital Pharmaceuticals of the Pharmaceutical Schedule. In summary, this proposal would result in:

1. no longer listing specific DV Pharmaceuticals in Part II;
2. the *Hospital Supply Status Products* table in Part II being deleted;
3. the section *Part II – Pharmaceuticals Under National Contracts* being formatted the same as Sections B, C and D of the Community Pharmaceutical Schedule (see attached example); and
4. the section *Part III – Assessed Pharmaceuticals* being deleted.

These changes are being considered as part of a project to publish Section H as an XML file that can be imported into DHB systems. The same XML file would be used in typesetting the printed version.

Feedback sought

PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by **Friday, 30 October 2009** to:

Rachel Mackay
Manager, Schedule and Contracts
PHARMAC
PO Box 10 254
Wellington 6143

Email: Rachel.mackay@pharmac.govt.nz

Fax: 04 460 4995

Details of the proposal

Removal of DV Pharmaceuticals

Unfortunately there is no robust process for including these items as we simply do not know everything that is available, and it changes over time. This can be misleading, as the list may not be comprehensive. The General Rules would be amended as follows:

“DV Pharmaceutical” means a discretionary variance Pharmaceutical, that does not have HSS and which:

- ~~(a) is either listed in Section H Part II of the Schedule as being a DV Pharmaceutical in association with the relevant Hospital Pharmaceutical with HSS; or~~
~~(b) is the same chemical entity, at the same strength, and in the same or a similar presentation or form, as the relevant Hospital Pharmaceutical with HSS, but which is not yet listed as being a DV Pharmaceutical.~~

Deletion of Part II - HSS Products table

The material in this section (including expiry dates) will be presented in Part II – Pharmaceuticals Under National Contracts, which has the same alphabetic organisation.

Reformatting Part II – Pharmaceuticals Under National Contracts

This will make the format of this section consistent with Sections B, C and D of the Community Pharmaceutical Schedule and may facilitate the two publications being combined in future. An draft example page has been attached.

Deletion of Part III – Assessed Pharmaceuticals

This material is available from other sources including the PHARMAC website.

SECTION H: Pharmaceuticals Under National Contracts

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
ABACAIVR SULPHATE WITH LAMIVUDINE			
Tab 600 mg with lamivudine 300 mg	630.00	30	Kivexa
ABCIXIMAB			
Inj 10 mg	579.53	1	ReoPro
ACARBOSE			
Tab 50 mg – 1% DV limit from Jul-09 to Jun-12.....	16.50	90	<u>Glucobay</u>
Tab 100 mg – 1% DV limit from Jul-09 to Jun-12.....	26.70	90	<u>Glucobay</u>
ACETAZOLAMIDE			
Tab 250 mg – 1% DV limit from Dec-08 to Jun-11	10.40	100	<u>Diamox</u>
ACETYLCYSTEINE			
Inj 200 mg per ml, 10 ml	219.75	10	Martindale Acetylcysteine
ACICLOVIR			
Tab dispersible 200 mg	1.98	25	Lovir
Tab dispersible 400mg	6.64	56	Lovir
Tab dispersible 800mg	7.38	35	Lovir
Inj 25 mg per ml, 10 ml	28.72	5	Mayne
ACITRETIN			
Cap 10 mg	75.80	100	Neotigason
Cap 25 mg	162.96	100	Neotigason
ACTIVATED CHARCOAL			
Oral liq 50 g per 250 ml	43.50	250 ml	Carbosorb-X
ADALIMUMAB			
Inj 40 mg per 0.8 ml prefilled syringe	1,799.92	2	Humira
Inj 40 mg per ml 0.8 ml prefilled pen	1,799.92	2	HumiraPen
ADEFOVIR DIPIVOXIL			
Tab 10 mg	670.00	30	Hepsera
ADRENALINE			
Inj 1 in 1,000, 1 ml	4.98	5	Aspen Adrenaline
	5.25		Mayne
Inj 1 in 10,000, 10 ml	27.00	5	Mayne
ALENDRONATE SODIUM WITH CHOLECALCIFEROL			
Tab 70 mg with cholecalciferol 5,600 iu	35.91	4	Fosamax Plus
Tab 70 mg with cholecalciferol 2,800 iu	35.91	4	Fosamax Plus
ALENDRONATE SODIUM			
Tab 70 mg	35.91	4	Fosamax
Tab 40 mg	133.00	30	Fosamax
ALFACALCIDIOL			
Cap 0.25 µg	26.32	100	One-Alpha
Cap 1 µg	87.98	100	One-Alpha
ALLOPURINOL			
Tab 100 mg – 1% DV limit from Mar-09 to Jun-11	5.44	250	<u>Apo-Allopurinol</u>
Tab 300 mg – 1% DV limit from Mar-09 to Jun-11	4.03	100	<u>Apo-Allopurinol</u>
ALPROSTADIL			
Inj 0.5 mg per ml, 1 ml – 1% DV limit from Sep-09 to Jun-11	1,417.50	5	<u>Prostin VR</u>